Newcells Biotech Ltd completes a licensing agreement with iPS Academia Japan, Inc. for induced pluripotent stem cell technologies

Newcells Biotech Ltd has signed a patent license agreement with iPS Academia Japan, Inc. to license and commercialise Kyoto University’s patented technologies in the field of induced pluripotent stem cells (iPSCs).

The agreement will enable Newcells to develop, manufacture, distribute products and offer services to customers in the pharmaceutical, biotechnology and academic sectors in Europe.

Dr Mike Nicholds CEO of Newcells Biotech commented on the signing of the license:

“The discovery of IPSCs in 2006 was a landmark event in the history of stem cell biology. Since that time the uptake of iPSC technology by academe and industry has accelerated with numerous applications in the fields of pre-clinical drug development. By completing this agreement Newcells Biotech can apply the scientific expertise of its co-founders to assist our customers to develop new disease modelling approaches and screening assays that are based on a source of reliable differentiated human cells produced at scale.”

The patents related to iPSC technologies licensed by iPS Academia Japan are the result of the break-through research of Professor Shinya Yamanaka of the Center for iPS Cell Research and Application (CiRA) at Kyoto University, Japan. iPSCs bear enormous potential for the elucidation of pathogenesis through disease modelling and the development of therapeutic strategies. Somatic cells can be induced into iPSCs by introduction of nuclear reprogramming factors, which iPSC’s can subsequently be differentiated into specific cell types of diverse lineages, making it possible to develop cell lines for, among other applications, screening potential treatments at the patient level. This approach, owing to its personalised nature, ensures greater predictive accuracy in disease modelling and treatment outcome.

You might also be interested in…

Development of functioning in vitro lung assay for modelling Covid-19 infection

Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform for modelling SARS-CoV-2 infection and replication.  Their work alongside the Liverpool School of Tropical Medicine (LTSM) Centre for Drugs and Diagnostics will be crucial in helping

The Biosphere

Newcells Biotech scales up its operations in The Biosphere

Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.    The purpose-built space in the city centre site

COVID-19 Vaccine

An Overview of Vaccine Development & Sub-Types

Vaccination can be regarded as one of biomedicines biggest triumphs. Since Edward Jenner pioneered the smallpox vaccine in 1798, subsequent morbidity and mortality rates have declined for a multitude of diseases, such as Diphtheria, Whooping Cough and Measles.1 However, despite the success of these global vaccination